Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,216 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effect of Sotagliflozin on Early Mortality and Heart Failure-Related Events: A Post Hoc Analysis of SOLOIST-WHF.
Pitt B, Bhatt DL, Szarek M, Cannon CP, Leiter LA, McGuire DK, Lewis JB, Riddle MC, Voors AA, Metra M, Lund LH, Komajda M, Testani JM, Wilcox CS, Ponikowski P, Lopes RD, Ezekowitz JA, Sun F, Davies MJ, Verma S, Kosiborod MN, Steg PG; SOLOIST-WHF Investigators. Pitt B, et al. Among authors: steg pg. JACC Heart Fail. 2023 Aug;11(8 Pt 1):879-889. doi: 10.1016/j.jchf.2023.05.026. JACC Heart Fail. 2023. PMID: 37558385 Free article. Clinical Trial.
Influence of body weight and body mass index on the chronic pharmacokinetic and pharmacodynamic responses to clinically available doses of ticagrelor in patients with chronic coronary syndromes.
Parker WAE, Angiolillo DJ, Rollini F, Franchi F, Bonaca MP, Bhatt DL, Steg PG, Orme RC, Thomas MR, Judge HM, Sabatine MS, Storey RF. Parker WAE, et al. Among authors: steg pg. Vascul Pharmacol. 2023 Apr;149:107145. doi: 10.1016/j.vph.2023.107145. Epub 2023 Jan 28. Vascul Pharmacol. 2023. PMID: 36720377
Cardiovascular Benefits of Icosapent Ethyl in Patients With and Without Atrial Fibrillation in REDUCE-IT.
Olshansky B, Bhatt DL, Miller M, Steg PG, Brinton EA, Jacobson TA, Ketchum SB, Doyle RT Jr, Juliano RA, Jiao L, Kowey PR, Reiffel JA, Tardif JC, Ballantyne CM, Chung MK; REDUCE‐IT Investigators. Olshansky B, et al. Among authors: steg pg. J Am Heart Assoc. 2023 Mar 7;12(5):e026756. doi: 10.1161/JAHA.121.026756. Epub 2023 Feb 21. J Am Heart Assoc. 2023. PMID: 36802845 Free PMC article. Clinical Trial.
Time to Benefit With Sotagliflozin in Patients With Worsening Heart Failure.
Verma S, Bhatt DL, Dhingra NK, Steg PG, Szarek M, Davies M, Metra M, Lund LH, Pitt B; SOLOIST Investigators. Verma S, et al. Among authors: steg pg. J Am Coll Cardiol. 2023 Apr 18;81(15):1546-1549. doi: 10.1016/j.jacc.2023.02.022. J Am Coll Cardiol. 2023. PMID: 37045523 Free article. No abstract available.
Relating Lipoprotein(a) Concentrations to Cardiovascular Event Risk After Acute Coronary Syndrome: A Comparison of 3 Tests.
Szarek M, Reijnders E, Jukema JW, Bhatt DL, Bittner VA, Diaz R, Fazio S, Garon G, Goodman SG, Harrington RA, Ruhaak LR, Schwertfeger M, Tsimikas S, White HD, Steg PG, Cobbaert C, Schwartz GG; ODYSSEY OUTCOMES Investigators. Szarek M, et al. Among authors: steg pg. Circulation. 2024 Jan 16;149(3):192-203. doi: 10.1161/CIRCULATIONAHA.123.066398. Epub 2023 Aug 26. Circulation. 2024. PMID: 37632469 Free PMC article.
Long-Term Efficacy, Safety, and Tolerability of Alirocumab in 8242 Patients Eligible for 3 to 5 Years of Placebo-Controlled Observation in the ODYSSEY OUTCOMES Trial.
Goodman SG, Steg PG, Poulouin Y, Bhatt DL, Bittner VA, Diaz R, Garon G, Harrington RA, Jukema JW, Manvelian G, Stipek W, Szarek M, White HD, Schwartz GG; ODYSSEY OUTCOMES Investigators. Goodman SG, et al. Among authors: steg pg. J Am Heart Assoc. 2023 Sep 19;12(18):e029216. doi: 10.1161/JAHA.122.029216. Epub 2023 Sep 13. J Am Heart Assoc. 2023. PMID: 37702079 Free PMC article. Clinical Trial. No abstract available.
1,216 results